Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Notes Payables (2024 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Notes Payables for 2 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • Quarterly Notes Payables fell 8.9% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2025, down 8.9% year-over-year, with the annual reading at $5.7 million for FY2025, 8.9% down from the prior year.
  • Notes Payables for Q4 2025 was $5.7 million at Nuvation Bio, up from $5.6 million in the prior quarter.
  • The five-year high for Notes Payables was $11.6 million in Q2 2024, with the low at $5.6 million in Q2 2025.